Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of United BioPharma.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
United BioPharma
Taiwan Flag
Country
Country
Taiwan
Address
Address
45-1 Guangfu N. Rd., Hukou Industrial Park (capital I) Hukou Township, Hsinchu County, 30351
Telephone
Telephone
+886-3-597-9288
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

UB-421 is an Fc-aglycosylated, non-T cell depleting and CD4-specific humanized IgG1 derived from the parent murine B4, which binds to discontinuous, conformational epitopes on the HIV-receptor complex, including CD4 (domain 1), and competitively blocks HIV entry.


Lead Product(s): UB-421,Chidamide

Therapeutic Area: Infections and Infectious Diseases Product Name: UB-421

Highest Development Status: Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 31, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

New results demonstrate a newer class of anti-IgE antibody, UB-221, with superior neutralization, synthesis reduction, and durable relief in targeting allergic diseases.


Lead Product(s): UB-221

Therapeutic Area: Immunology Product Name: UB-221

Highest Development Status: Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 05, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

UB-221 shows 2 to 5-folds inhibition of IgE synthesis than Xolair in the in vitro study. UB-221 only takes 1/10 dose to achieve the same effect of Xolair in huIGHE-knock-in mice model. PK study in cynomolgus monkeys demonstrated UB-221 has a longer serum half-life than Xolair.


Lead Product(s): UB-221

Therapeutic Area: Immunology Product Name: UB-221

Highest Development Status: Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 27, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

UB-621 is a first-in-class anti-gD mAb a best-in-class long-acting treatment for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and HSV2).


Lead Product(s): UB-621

Therapeutic Area: Infections and Infectious Diseases Product Name: UB-621

Highest Development Status: Phase IProduct Type: Large molecule

Partner/Sponsor/Collaborator: Shanghai Public Health Clinical Centre

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 18, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

UB-421 is a strong entry inhibitor of HIV with proven ability to substitute for ART, and it may also enhance CD8 T cell cytotoxicity function and improve immune exhaustions .


Lead Product(s): UB-421,Chidamide

Therapeutic Area: Infections and Infectious Diseases Product Name: UB-421

Highest Development Status: Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 18, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The current Phase 2 study is a randomized, single-blinded, placebo-controlled study to investigate the efficacy and safety of single dose UB-621 treatment for recurrent genital herpes.


Lead Product(s): UB-621

Therapeutic Area: Infections and Infectious Diseases Product Name: UB-621

Highest Development Status: Phase IProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 11, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

United BioPharma has received Investigational New Drug approval from the China National Medical Products Administration to conduct a Phase 3 clinical trial with UB-421, an anti-CD4 monoclonal antibody, in patients with multi-drug resistant HIV-1 infection.


Lead Product(s): UB-421

Therapeutic Area: Infections and Infectious Diseases Product Name: UB-421

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 21, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

This trial is an open label, multi-dose study, to evaluate the safety, pharmacokinetics, and antiviral activity of UB-421 SC in HIV-1 positive, asymptomatic adults who have no prior or current treatment with anti-retroviral drugs.


Lead Product(s): UB-421

Therapeutic Area: Infections and Infectious Diseases Product Name: UB-421

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 05, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY